3.Studies on personality tests in medical student selection. III. Influences of interviewers' character on evaluation and a trial of making suitable pair of interviewers.
Tsunao TETSUKA ; Keiko YOSHINO ; Shigenori IKEMOTO ; Naoshi SATOH ; Tokunosuke ABE ; Osamu AONO ; Hiroshi FUJIMOTO
Medical Education 1985;16(5):377-383
4.Human relation and scholarly achievement.
Tokunosuke ABE ; Osamu AONO ; Hiroshi FUJIMOTO ; Keiko YOSHINO ; Naoshi SATOH ; Shigenori IKEMOTO ; Tsunao TETSUKA
Medical Education 1986;17(3):157-162
5.Study on Conditions to Increase the Domestic Production of Herbal Materials by Changing Crops Production from Tobacco
Hiroshi KOIKE ; Yuta YOSHINO ; Kotaro MATSUMOTO ; Tomohiro TAKEHARA ; Osamu TAKEMOTO ; Keiko MATSUURA ; Kenji WATANABE
Kampo Medicine 2012;63(4):238-244
Herb supplies can become unstable because of climate change and the economic development of herb exporters. In this paper, in order to increase the self-sufficiency of herbal resources we examined the possibil ity of changing to herb crop production from tobacco, for which demand is declining. Firstly, we considered demand, quality and the price of raw herb materials to make recommendations for corrections, and selected Angelica (A. ) acutiloba and Bupleurum (B. ) falcatum Linne. Next, we compared the profitability of tobacco and the herbs. Profit margins for A. acutiloba were less than for tobacco. It was thought that the profitability of A. acutiloba could become equivalent to tobacco if an adjustment subsidy were provided. The self-sufficiency rate for A. acutiloba would be one hundred percent with 35 million yen in every year. Although the profitabil ity of B. falcatum has exceeded tobacco, its selling price was about 3 times that of imports, while the price of medical B. falcatum was lower than its selling price. It was thought that the price competitiveness problem of B. falcatum can be covered if a production subsidy is provided, and to reach a 50 percent B. falcatum self sufficiency rate with 660 million yen per year.
6.A Survey of the Collection, Provision, and Application of Drug Safety Information at Hospitals
Maki Masuyama ; Hirokazu Hasegawa ; Mie Ikeda ; Kazuhiko Mori ; Keiko Yoshino ; Yoshiaki Ara ; Hisanori Miyashita ; Yasuo Ide ; Yoshihiko Suzuki ; Masahiro Hayashi ; Tsutomu Matsuda
Japanese Journal of Drug Informatics 2013;14(4):170-178
Objective: We conducted a questionnaire survey to comprehend the situation regarding the collection, provision, and utilization of drug safety information at hospitals. In addition, we asked pharmaceutical companies how they select medical institutions to provide drug safety information. We also investigated the current situation of information provision to Tokyo Medial Center by pharmaceutical companies.
Method: A questionnaire was mailed to all hospitals in Japan. The survey was conducted between January 13 and February 10, 2011. Moreover, we asked thirteen pharmaceutical companies by telephone and e-mail about the implementation status of the provision of information and performed a survey at Tokyo Medical Center on the current situation of information provision by pharmaceutical companies regarding revisions to precaution sections in package inserts.
Results: The results of the questionnaire survey (response rate: 41.2%) showed that the major information sources for hospitals were medical representatives (77.8%), Drug Safety Update (50.3%) and direct mails (49.3%). Furthermore, in the case of drugs prescribed exclusively for extramural dispensing, fewer hospitals responded that medical representatives of the pharmaceutical companies provided drug safety information and more hospitals responded that they did not obtain any drug safety information at all, compared with drugs listed in the hospital formularies.
Conclusion: To minimize the risks of drugs, healthcare professionals must collect a wide range of drug safety information and must utilize this information in their medical practice. Therefore, it is important that pharmaceutical companies and regulatory authorities make an effort to provide suitable information dissemination to medical institutions. Furthermore, medical institutions must also strengthen their systems for collecting drug safety information and providing such information to healthcare professionals.